Cinclus Pharma Holding AB (publ) (STO:CINPHA)

Sweden flag Sweden · Delayed Price · Currency is SEK
16.80
-0.70 (-4.00%)
At close: Mar 3, 2026
15.23%
Market Cap 813.48M
Revenue (ttm) 57.47M
Net Income (ttm) -183.97M
Shares Out 46.54M
EPS (ttm) -3.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,699
Average Volume 36,426
Open 17.48
Previous Close 17.50
Day's Range 16.34 - 17.48
52-Week Range 9.31 - 19.64
Beta n/a
RSI 45.73
Earnings Date Feb 18, 2026

About Cinclus Pharma Holding AB

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and... [Read more]

Sector Healthcare
Founded 2014
Employees 21
Stock Exchange Nasdaq Stockholm
Ticker Symbol CINPHA
Full Company Profile

Financial Performance

In 2025, Cinclus Pharma Holding AB's revenue was 57.47 million, an increase of 1154.80% compared to the previous year's 4.58 million. Losses were -183.97 million, 9.49% more than in 2024.

Financial Statements

News

There is no news available yet.